Literature DB >> 15724099

The mystical effects of dermatological vehicles.

Christian Surber1, Eric W Smith.   

Abstract

Topical treatment of the skin is as old as the evolution of man. Instinctively, we try to treat a skin injury or irritation with cooling or soothing substances. Even animals lick their wounds, trusting instinctively in the healing power of saliva. When did this archaic pattern of treatment take the gigantic leap from folk medicine to modern drug therapy? This text illustrates the evolution of topical dermatological vehicles, their application (guidelines) and future use. In particular, a phenomenon that has so far been ignored in product development and clinical testing is the vehicle metamorphosis. In clinical and experimental situations, most dermatological vehicles undergo considerable changes after they have been removed from the primary container and are applied to the skin. Subsequently, the initial structural matrix, and the quantitative composition of the vehicle, will most likely change during and after the mechanical shear associated with application of the product and/or evaporation of ingredients. This natural, but highly dynamic process will generate mini-environments for the active moiety that are difficult to predict and that are crucial to the fate of the active moiety. Despite the reasonable wishes of formulators, clinicians, patients and customers, there are still no universal vehicles. Each drug, at each concentration, requires a different vehicle for optimized therapy. Stability and compatibility of excipients and active moiety are crucial for any commercially available pharmaceutical or cosmetic formulation, together with local and systemic safety of all components. Nonetheless, more diverse and molecularly complex classes of new dermatological vehicles are continuously being researched and refined. The scientific progress has been remarkable when one considers the simple emulsion mixtures that were commonplace in dermatological therapy and still persist to this day in commercial products. It is to be hoped that the result of these research endeavors will be the emergence of more innovative topical formulations, applying engineered bioavailability control systems, with broader applications in topical therapeutic and cosmetic vehicles.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15724099     DOI: 10.1159/000082572

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  9 in total

1.  Colorimetric polymer films for predicting lipid interactions and percutaneous adsorption of pharmaceutical formulations.

Authors:  Izek Ben-Shlush; Roman Volinsky; Marina Katz; Yogesh Scindia; Racheli Itzhak; Hila Tsahor Ohayon; Ido Yosha; Raz Jelinek
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

2.  Soy Phosphatidylglycerol Reduces Inflammation in a Contact Irritant Ear Edema Mouse Model In Vivo.

Authors:  Ding Xie; Vivek Choudhary; Mutsa Seremwe; John G Edwards; Angela Wang; Aaron C Emmons; Katherine A Bollag; Maribeth H Johnson; Wendy B Bollag
Journal:  J Pharmacol Exp Ther       Date:  2018-04-25       Impact factor: 4.030

3.  Assessment of Drug Delivery Kinetics to Epidermal Targets In Vivo.

Authors:  M Hoppel; M A M Tabosa; A L Bunge; M B Delgado-Charro; R H Guy
Journal:  AAPS J       Date:  2021-03-29       Impact factor: 4.009

4.  Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients.

Authors:  Marianne Lind; Kim Troensegaard Nielsen; Line Hollesen Schefe; Kasper Nørremark; André Huss Eriksson; Hanne Norsgaard; Brian Thoning Pedersen; Karsten Petersson
Journal:  Dermatol Ther (Heidelb)       Date:  2016-06-29

5.  Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments.

Authors:  C Queille-Roussel; B Bang; F Clonier; J-P Lacour
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-15       Impact factor: 6.166

Review 6.  Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy.

Authors:  Siegfried Segaert; Neil H Shear; Andrea Chiricozzi; Diamant Thaçi; Jose-Manuel Carrascosa; Helen Young; Vincent Descamps
Journal:  Dermatol Ther (Heidelb)       Date:  2017-08-07

7.  The Influence of Formulation and Excipients on Propranolol Skin Permeation and Retention.

Authors:  Cristina Padula; Sara Nicoli; Silvia Pescina; Patrizia Santi
Journal:  Biomed Res Int       Date:  2018-08-02       Impact factor: 3.411

Review 8.  Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison.

Authors:  Tanya M Barnes; Dalibor Mijaljica; Joshua P Townley; Fabrizio Spada; Ian P Harrison
Journal:  Pharmaceutics       Date:  2021-11-26       Impact factor: 6.321

9.  Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model.

Authors:  Nuria Gago-López; Carmen Lagunas Arnal; Juan J Perez; Erwin F Wagner
Journal:  Exp Dermatol       Date:  2021-05-28       Impact factor: 3.960

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.